Show simple item record

 
dc.contributorDepartament de Salut
dc.date.accessioned2019-04-04T09:52:23Z
dc.date.available2019-04-04T09:52:23Z
dc.date.issued2018-11-28
dc.identifier.citationCladribina per al tractament de l'esclerosi múltiple en pacients adults. Barcelona: Servei Català de la Salut; 2018.
dc.identifier.urihttps://hdl.handle.net/11351/4027
dc.descriptionCladribine; Multiple sclerosis; Adult patients
dc.description.abstractMultiple sclerosis (MS) is a chronic central nervous system (CNS) disease that is It is characterized by inflammation, demyelination, glial scarring and neuroaxonal degeneration. Its etiology is not entirely known, although it is thought to be an autoimmune disease triggered by an unknown environmental factor associated with a genetic predisposition.
dc.language.isocat
dc.publisherServei Català de la Salut
dc.relation.ispartofPrograma d'harmonització farmacoterapèutica, Servei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMedicaments - Assaigs clínics
dc.subjectCitotoxicitat
dc.subjectEsclerosi múltiple - Tractament
dc.subject.meshMultiple Sclerosis
dc.subject.meshCladribine
dc.subject.mesh/drug therapy
dc.subject.meshDrug Evaluation
dc.titleCladribina per al tractament de l'esclerosi múltiple en pacients adults
dc.typeinfo:eu-repo/semantics/report
dc.subject.decscladribina
dc.subject.decsesclerosis múltiple
dc.subject.decs/uso terapéutico
dc.subject.decsevaluación de medicamentos
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record